Publications by authors named "A Voloschin"

Article Synopsis
  • This study assessed the safety of using immune checkpoint inhibitors (ICIs) — specifically anti-CTLA-4 and anti-PD-1 — for treating newly diagnosed glioblastoma (GBM) patients after standard treatment, aiming to explore combined therapies.
  • A total of 32 patients participated, showing that the treatments were generally well tolerated, with low rates of severe toxicity and no deaths related to the treatments; specifically, the combination treatment did not show increased toxicity compared to single-agent therapies.
  • The findings indicate that the combination of Ipilimumab and Nivolumab could provide promising results for overall and progression-free survival in patients with GBM, supporting further trials to evaluate their efficacy in this setting.
View Article and Find Full Text PDF
Article Synopsis
  • A randomized phase II clinical trial investigated the effectiveness of cediranib, a drug targeting vascular growth factors, when combined with radiation and temozolomide in newly diagnosed glioblastoma patients.
  • Out of 158 participants, 137 were eligible, showing a 6-month progression-free survival (PFS) rate of 46.6% for cediranib versus 24.5% for the placebo, indicating a significant improvement.
  • Although cediranib improved PFS, there was no notable difference in overall survival, and patients receiving cediranib experienced more serious adverse events compared to those on placebo.
View Article and Find Full Text PDF

Cellular agriculture could meet growing demand for animal products, but yields are typically low and regulatory bodies restrict genetic modification for cultured meat production. Here we demonstrate the spontaneous immortalization and genetic stability of fibroblasts derived from several chicken breeds. Cell lines were adapted to grow as single-cell suspensions using serum-free culture medium, reaching densities of 108 × 10 cells per ml in continuous culture, corresponding to yields of 36% w/v.

View Article and Find Full Text PDF

Multidisciplinary tumor boards (TB) are an essential part of brain tumor care, but quantifying the impact of imaging on patient management is challenging due to treatment complexity and a lack of quantitative outcome measures. This work uses a structured reporting system for classifying brain tumor MRIs, the brain tumor reporting and data system (BT-RADS), in a TB setting to prospectively assess the impact of imaging review on patient management. Published criteria were used to prospectively assign three separate BT-RADS scores (an initial radiology report, secondary TB presenter review, and TB consensus) to brain MRIs reviewed at an adult brain TB.

View Article and Find Full Text PDF